Kineta, Inc. (KA)
NASDAQ: KA · IEX Real-Time Price · USD
0.590
+0.013 (2.25%)
At close: Jul 2, 2024, 4:00 PM
0.552
-0.038 (-6.44%)
After-hours: Jul 2, 2024, 6:25 PM EDT
Kineta Revenue
Kineta had revenue of $5.16M in the twelve months ending March 31, 2024, with 186.56% growth year-over-year. In the year 2023, Kineta had annual revenue of $5.44M with 178.65% growth.
Revenue (ttm)
$5.16M
Revenue Growth
+186.56%
P/S Ratio
1.40
Revenue / Employee
$469,182
Employees
11
Market Cap
7.23M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 5.44M | 3.49M | 178.65% |
Dec 31, 2022 | 1.95M | -7.14M | -78.52% |
Dec 31, 2021 | 9.09M | 2.20M | 31.83% |
Dec 31, 2020 | 6.90M | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 2.84M | -2.50M | -46.83% |
Dec 31, 2017 | 5.34M | -3.04M | -36.30% |
Dec 31, 2016 | 8.38M | 4.07M | 94.43% |
Dec 31, 2015 | 4.31M | -838.00K | -16.27% |
Dec 31, 2014 | 5.15M | 4.01M | 351.36% |
Dec 31, 2013 | 1.14M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionKA News
- 6 weeks ago - Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities - GlobeNewsWire
- 3 months ago - Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial - GlobeNewsWire
- 3 months ago - Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported - GlobeNewsWire
- 4 months ago - Kineta Announces Restructuring and Exploration of Strategic Alternatives - GlobeNewsWire
- 4 months ago - Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium - GlobeNewsWire
- 4 months ago - Kineta to Present at Upcoming Investor Conferences - GlobeNewsWire
- 5 months ago - Kineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat Series - GlobeNewsWire